. Author manuscript; available in PMC: 2015 Oct 1.

Published in final edited form as: Schizophr Res. 2014 Aug 27;159(1):243–248. doi: 10.1016/j.schres.2014.08.003

Table 1.

Group differences in demographic, clinical and neuropsychological variables.

	Schizophrenia	Control	Test statistic	p value
Total N	126	151	n/a	n/a
Age [years](±sd)	37.9 (13.3)	35.8(13.8)	t=1.25	.214
%Male	55.5	34.4	χ2=12.5	.002
%Smoker	43.7	27.8	χ2=7.36	.007
CPZ [mg]	542	n/a	n/a	n/a
MTSD-Trait	1.11	0.70	χ²=16.48	<.001
MTSD-State	0.92	0.43	χ²=33.49	<.001
Working memory	36.6	45.4	t=5.67	<.001
Processing speed	7.4	10.5	t=8.01	<.001
Functional capacity	86.7	101.5	t=8.31	<.001

CPZ = chlorpromazine dose equivalent of antipsychotic medication. Working memory was assessed using the Digit Sequencing task from the Brief Assessment of Cognition in Schizophrenia, processing speed was assessed with the Digit Symbol Coding task (WAIS-3), and functional capacity was measured using the UPSA-2.